Archives
-
Bovine Insulin for ER-Stress-Aware Cell Culture
2026-08-26
Bovine insulin is more than a routine media additive: it can help define the metabolic context in ER-stress and inflammatory assays. This guide connects insulin signaling, HMGB1 biology, and practical cell-culture design without overstating what current evidence proves.
-
Structure-Guided Proteomimetics Block SARS-CoV-2 Entry
2026-08-26
The reference study develops constrained proteomimetics that reproduce key human ACE2 recognition elements and disrupt the SARS-CoV-2 Spike receptor-binding domain interaction. Its lead construct, compound 28, combined selective RBD binding with pseudovirus-entry inhibition, epithelial stability, and low permeability, supporting further investigation of proteomimetics for difficult protein–protein interaction targets.
-
Leupeptin Hemisulfate in Protease Workflows
2026-08-25
Leupeptin, Microbial, provides reversible control of serine and cysteine proteases for cleaner protein degradation, autophagy, and biochemical assays. This guide translates its inhibition profile into practical workflows and shows how orthogonal binding and activity measurements from a TET2 protocol can improve experimental confidence.
-
Leupeptin Hemisulfate Salt: Lab Guide
2026-08-25
A scenario-based guide to using Leupeptin, Microbial (Leupeptin hemisulfate), SKU A2570, when protease activity may confound cell viability, proliferation, cytotoxicity, autophagy, or viral assays. It covers mechanism, compatibility, dosing logic, interpretation, and practical supplier selection.
-
MG-132 Workflows for Proteasome and Apoptosis Studies
2026-08-24
MG-132, also known as Z-LLL-al, connects proteasome blockade with protein accumulation, oxidative stress, apoptosis, and cell-cycle phenotypes. This practical guide translates those effects into controlled assay workflows and shows how the compound can test proteasome-dependent ER stress responses without being mistaken for a direct ER stress inducer.
-
MLKL Polymerization and Lysosomal LMP in Necroptosis
2026-08-24
The reference study identifies lysosomal membrane permeabilization as a critical intermediate between MLKL polymerization and plasma membrane rupture during necroptosis. Its imaging, loss-of-function, and MLKL domain experiments support a model in which released cathepsin B helps execute cell death, while also clarifying how protease-focused controls should be interpreted.
-
BMAL1 Phase Separation in Circadian Transcription
2026-08-23
Gao et al. identify BMAL1 as a phase-separating clock factor that forms dynamic nuclear condensates and couples circadian DNA binding to transcriptional output. Their deletion, optogenetic clustering, cellular rescue, and mouse studies implicate the N-terminal intrinsically disordered region and its phosphorylation state in organizing transcriptional hubs required for rhythmic gene expression and locomotor behavior.
-
Tropifexor: FXR Strategy for Gut–Liver Research
2026-08-22
Tropifexor (LJN452) offers a high-potency way to interrogate FXR biology across intestinal barrier, liver, and metabolic disease models. This article connects receptor-level experimentation with recent evidence that nutrient-derived metabolites can act as metabolic signals, providing a strategic framework for translational study design without overstating clinical relevance.
-
FPH1 (BRD-6125) Hepatocyte Expansion Guide
2026-08-22
FPH1 (BRD-6125) combines hepatocyte proliferation with functional readouts, making it useful for primary human hepatocyte culture and iPSC-derived hepatocyte workflows. This guide explains dosing, assay design, troubleshooting, and how to interpret albumin, CYP3A4, AFP, nuclei-count, and mitotic responses without overstating the evidence.
-
Solanesol Workflow Guide for Hydrophobic Assays
2026-08-21
Solanesol is a high-purity polyisoprenoid alcohol for research workflows that require controlled handling of a hydrophobic compound, including membrane-related assays, apoptosis research, DNA damage and repair studies, metabolic enzyme assays, and protease activity research. It is insoluble in water and ethanol, so it should be prepared in DMSO and used with solvent-matched controls; this product is not intended for diagnostic, clinical, or medical use.
-
Camostat Mesilate: Mechanism and Research Use
2026-08-20
Camostat Mesilate is a trypsin-like protease inhibitor used to study ENaC-linked protease signaling, plasmin activity, TGF-β generation, and hepatic fibrosis. The product dossier reports a 50 nM IC50 for airway epithelial sodium channel function and high solubility in DMSO and water, while distinguishing this protease-directed mechanism from structure-guided viral protein–protein interaction inhibitors.
-
Ionomycin calcium salt: Calcium Signaling
2026-08-20
Ionomycin calcium salt is a calcium ionophore that raises intracellular Ca2+ through cellular-membrane transport, release of regulated calcium pools, and extracellular influx. Product information and cancer-model evidence support its use for controlled calcium signaling studies, while the cited prostate-cancer study establishes calcium-pathway relevance rather than direct ionomycin efficacy.
-
Fusobacterium EVs Prepare Colorectal Cancer Niches
2026-08-19
Zheng et al. show that extracellular vesicles from Fusobacterium nucleatum accumulate in colorectal cancer and help establish tumor sites that favor bacterial adhesion. Their results identify vesicle-mediated transfer of the adhesin FomA to cancer-cell surfaces as a mechanism linking microbial communication with intratumoral colonization.
-
AEBSF.HCl in Protease and Necroptosis Workflows
2026-08-19
AEBSF.HCl gives researchers irreversible control over broad serine-protease activity in APP processing, leukemic-cell lysis, and cell-culture experiments. Used alongside lysosomal imaging and cathepsin-specific controls, it can distinguish serine-protease effects from the cathepsin B pathway implicated in necroptosis.
-
Elbasvir–Grazoprevir in HCV: Evidence and Practice
2026-08-18
The 2021 review by Wang, Huang, and Yu explains how combining the NS5A inhibitor elbasvir with the NS3/4A protease inhibitor grazoprevir produces a potent, once-daily interferon-free regimen for HCV genotypes 1 and 4. Its practical significance lies in consistently high virologic response, activity in difficult-to-treat populations, renal safety, and the complementary mechanisms that help limit resistance.